Anti limfomny drug is effective against chronic fatigue syndrome. According to researchers, this supports the hypothesis that this syndrome may be caused by problems with the immune system.
Cancer means eliminating the chronic fatigue syndrome. Scientists from the University of Bergen (Norway) noted that rituximab, a drug against lymphoma, relieves symptoms of chronic fatigue syndrome in 10 out of 15 patients.
Rituximab is an antibody which binds to mature B cells. This leads to the fact that an excess of "malignant" B cells are destroyed. Researchers in a sense lucky that the University Hospital of patients with lymphoma were patients suffering from chronic fatigue and more. Two of them were treated with the drug last three years, got rid of this neurological disorder.
Although this work and has great statistics, based on the obtained results suggest several important conclusions. The first is: Chronic fatigue syndrome is caused by pereproduktsiey antibodies, which occurs from an excess of B-lymphocytes. These antibodies may mistakenly attack the body's own tissues. This explains why rituximab, according to the researchers, began to act a few months after the first dose: the extra B-cells, he cleaned a couple of weeks, but the antibodies that the cells had synthesized, wandered through the bloodstream has a couple of months. Once these antibodies are naturally eroded, became noticeable, and medication.
The second conclusion is that researchers do in his article, is that chronic fatigue syndrome, apparently you can not blame a virus. There is a popular hypothesis that the disease is called XMRV, mouse leukemia virus. The authors were unable to find any traces of the virus in patients who participated in the study. Moreover, some time ago it became clear that the previous results, linking the virus with chronic fatigue syndrome, were largely wrong: the virus has been introduced in the course of the experiment from the outside and to the symptoms of the disease had no relationship.
Given the sad fate of these studies, the authors call for greater caution with the conclusions about the causes of the syndrome. To start with, they want to know why the drug acted not at all in patients with chronic fatigue. Although, according to scientists who might work here in the dosage.